Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 5/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340019 | 0.89 | CHRNB2 (0.55) | HTR2ATAAR1CYP2D6TDP1CHRNB2 | |
| SCHEMBL28772579 | 0.89 | HTR2A (0.59) | HTR2ATDP1 | |
| SCHEMBL5995430 | 0.87 | CNR1 (0.45) | HTR2ACYP2C19TSHR | |
| SCHEMBL6701579 | 0.87 | IDO1 (0.46) | CYP2D6CYP2C19L3MBTL1TDP1TSHR | |
| SCHEMBL4604382 | 0.87 | SLC6A3 (0.55) | KDM4ETSHR | |
| SCHEMBL27546481 | 0.84 | LOXL2 (0.46) | HTR2ATAAR1CYP2D6HRH1CYP2C19 | |
| SCHEMBL6338658 | 0.82 | KMT2A (0.43) | CYP2C19KDM4E | |
| SCHEMBL15574233 | 0.82 | IDO1 (0.45) | HTR2ATAAR1CYP2D6HRH1CYP2C19 | |
| SCHEMBL6699162 | 0.82 | ACP3 (0.47) | — | |
| SCHEMBL6703510 | 0.82 | ACP3 (0.51) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3809876-A1 | PROTECTIVE AGENT FOR FOOD PRODUCTS AND THE LIKE AND FOR CURING AND/OR STORAGE ROOMS OF THE SAME | PERPRIN S.R.L. (IT) | 2021-04-28 | — | — | EP | claimed |
| WO-2019243869-A1 | PROTECTIVE AGENT FOR FOOD PRODUCTS AND THE LIKE AND FOR CURING AND/OR STORAGE ROOMS OF THE SAME | PERPRIN S.R.L. (IT) | 2019-12-26 | — | — | WO | claimed |
| EP-3283622-A1 | MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO | F. Hoffmann-La Roche AG (CH) | 2018-02-21 | — | — | EP | claimed |
| WO-2016166120-A1 | MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-20 | — | — | WO | claimed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | claimed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | claimed |
| CN-101160300-B | A method for preparing hydroxylated isoflavone | DSM IP ASSETS BV | 2012-06-27 | — | — | CN | claimed |
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | claimed |
| EP-2346892-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-07-27 | — | — | EP | claimed |
| US-5047397-A | Natriuretics, diuretics, vasodilators | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1991-09-10 | — | — | US | claimed |
| EP-0410989-A4 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | — | 1991-06-05 | — | — | EP | claimed |
| EP-0410989-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1991-02-06 | — | — | EP | claimed |
| US-4935492-A | Cyclic analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1990-06-19 | — | — | US | claimed |
| WO-1989009611-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-10-19 | — | — | WO | claimed |
| EP-0323740-A2 | Linear analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1989-07-12 | — | — | EP | claimed |
| WO-1989005654-A1 | LINEAR ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-06-29 | — | — | WO | claimed |
| US-4804650-A | DIURETICS, VASODILATORS | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1989-02-14 | — | — | US | claimed |
| US-4438136-A | INHIBITION OF THROMBOXANE ACTIVITY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-20 | — | — | US | claimed |
| EP-0013608-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-06-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | FCGR1A, FCGR2A, FCGR3B | HTR2A 4793/4885TAAR1 3124/4885CYP2D6 4788/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | HTR2A 3407/4885TAAR1 3263/4885CYP2D6 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.